A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma

Authors :: T. Cloughesy
Antonio Omuro
Patrick Y. Wen
Phioanh L. Nghiemphu
Linh Nguyen
Andrew D. Norden
Ingo K. Mellinghoff
K. Rajangam
Source :: Journal of Clinical Oncology. 28:3085-3085
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: 3085 Background: PI3K pathway dysregulation has been implicated in resistance to TMZ in preclinical glioma models. XL765, a potent and selective inhibitor of class I PI3K isoforms and TORC1 and TOR...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Temozolomide
business.industry
Newly diagnosed
medicine.disease
Pharmacokinetics
Glioma
Internal medicine
medicine
In patient
business
PI3K/AKT/mTOR pathway
medicine.drug

Full Text Access

Tools